Genetic Testing - G2 Intelligence

Private Payer Reimbursement for Genetic Testing Hinges on Clinical Utility

Two revenue cycle management experts offer tips for clinical labs to improve coverage decisions for genetic tests

Start a Free Trial for immediate access to this article

Already a member? Log in here

Experts—including those in genetics and device regulation—say the AvertD assay did not predict risks of abuse ‘any better than chance’

Start a Free Trial for immediate access to this article

Already a member? Log in here

How the MolDX® program works, what it covers, and how it can support better test access, use, and reimbursement in the clinical lab

Start a Free Trial for immediate access to this article

Already a member? Log in here

Lab leaders should be wary of telemedicine arrangements, certain marketing firms, and unnecessary PGx and CGx testing

Start a Free Trial for immediate access to this article

Already a member? Log in here

In an era when genetic and genomic testing are theoretically affordable and accessible, why do so many patients remain undiagnosed?

Start a Free Trial for immediate access to this article

Already a member? Log in here